Kymera Therapeutics, Inc. announced on September 17, 2025, that it will deliver late-breaking oral presentations on KT-621, its first-in-class oral STAT6 degrader, at the European Academy of Dermatology & Venereology (EADV) and European Respiratory Society (ERS) Congresses. These presentations will showcase the positive Phase 1 healthy volunteer trial results, supporting KT-621’s oral, dupilumab-like profile.
The positive Phase 1 healthy volunteer data demonstrated robust STAT6 degradation in blood and skin, along with reductions in multiple Th2 disease-relevant biomarkers and a favorable safety profile. These results significantly de-risk the program and validate Kymera's strategy to develop oral medicines with biologics-like activity.
The KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients remains on track to report data in the fourth quarter of 2025. Additionally, the KT-621 Phase 2b trials in AD and asthma are on track to initiate in the fourth quarter of 2025 and the first quarter of 2026, respectively, further advancing this key program towards later-stage development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.